Structured treatment interruptions for the management of HIV infection

JAMA

Volumn 286, Issue 23, 2001, Pages 2981-2987

  Lori, Franco ^b   Lisziewicz, Julianna ^b  

^a Research Institute for Genetic Human Therapy   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA; INDINAVIR; STAVUDINE;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035915372     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.23.2981     Document Type: Article

References (44)

1. Hostparasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine
2. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
3. Control of HIV despite the discontinuation of antiretroviral therapy
4. SSITT: A prospective trial of strategic treatment interruptions in 128 patients
5. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
6. Immune control of HIV-1 after early treatment of acute infection
7. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
8. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
9. Control of SIV rebound through structured treatment interruptions during early infection
10. Short-cycle intermittent HAART
11. HIV suppressed long after treatment
12. Immunology taught by viruses
13. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion
14. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
15. Structured treatment interruptions to control HIV
16. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
17. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
18. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
19. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
20. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
21. Skewed maturation of memory HIV-specific CD8 T lymphocytes
22. The T cell receptor V beta repertoire in HIV-1 infection and disease
23. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences
24. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
25. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
26. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
27. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
28. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
29. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
30. Host factors in the pathogenesis of HIV disease
31. Antiretroviral therapy in adults
32. Factors affecting adherence to antiretroviral therapy
33. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
34. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
35. Influence of hydroxyurea (HU) associated with HAART and maintained during periods off antiretroviral therapy in STI on the HIV-1-specific immune responses
36. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity
37. Restoration of immunity after HIV infection
38. 6/L CD4 cell counts
39. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
40. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells
41. Immunogenicity and antiviral efficacy of a novel transcutaneous DNA immunization
42. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
43. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine